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Abstract
Background:  An evidence-based clinical practice guideline on the optimal radiotherapeutic
management of single and multiple brain metastases was developed.
Methods: A systematic review and meta-analysis was performed. The Supportive Care Guidelines
Group formulated clinical recommendations based on their interpretation of the evidence. External
review of the report by Ontario practitioners was obtained through a mailed survey, and final
approval was obtained from Cancer Care Ontario's Practice Guidelines Coordinating Committee
(PGCC).
Results: One hundred and nine Ontario practitioners responded to the survey (return rate 44%).
Ninety-six percent of respondents agreed with the interpretation of the evidence, and 92% agreed
that the report should be approved. Minor revisions were made based on feedback from external
reviewers and the PGCC. The PGCC approved the final practice guideline report.
Conclusions: For adult patients with a clinical and radiographic diagnosis of brain metastases
(single or multiple) we conclude that,
• Surgical excision should be considered for patients with good performance status, minimal or no
evidence of extracranial disease, and a surgically accessible single brain metastasis.
• Postoperative whole brain radiotherapy (WBRT) should be considered to reduce the risk of
tumour recurrence for patients who have undergone resection of a single brain metastasis.
• Radiosurgery boost with WBRT may improve survival in select patients with unresectable single
brain metastases.
• The whole brain should be irradiated for multiple brain metastases. Standard dose-fractionation
schedules are 3000 cGy in 10 fractions or 2000 cGy in 5 fractions.
• Radiosensitizers are not recommended outside research studies.
• In select patients, radiosurgery may be considered as boost therapy with WBRT to improve local
tumour control. Radiosurgery boost may improve survival in select patients.
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• Chemotherapy as primary therapy or chemotherapy with WBRT remains experimental.
• Supportive care is an option but there is a lack of Level 1 evidence as to which subsets of patients
should be managed with supportive care alone.
Qualifying statements addressing factors to consider when applying these recommendations are 
provided in the full report. The rigorous development, external review and approval process has 
resulted in a practice guideline that is strongly endorsed by Ontario practitioners.
Background
Brain metastases represent a significant health care prob-
lem. An estimated 20–40% of cancer patients will develop
multiple brain metastases [1], and 30–40% will develop a
single metastasis [2] during the course of their illness. The
prognosis for patients is generally poor, and treatment
decisions are based on a combination of factors, including
survival, quality of life, intracranial progression-free dura-
tion, response of brain metastases to treatment, symptom
control, neurological function, and toxicity. These out-
comes were considered in the systematic review that
informed this provincial clinical practice guideline, which
was initiated to summarize the evidence and to provide
recommendations on the optimal management of brain
metastases.
The systematic review and meta-analyses, conducted as
the initial step in formulating this practice guideline, are
described in a companion document that has been sub-
mitted elsewhere for publication [3]. It is also currently
undergoing review with the Cochrane Collaboration.
Briefly, the evidence was broadly divided into studies
aimed at management of a single brain metastasis [4-7]
versus those aimed at management of multiple brain
metastases [8-33] arising from cancer of any histology.
The following interventions were compared in the rand-
omized controlled trials included in the systematic
review: for single brain metastasis, whole brain radiother-
apy (WBRT) with or without surgery [4-6] and surgery
with or without WBRT [7]; for multiple brain metastases,
supportive care with or without WBRT [8], various altered
dose-fractionation schedules [9-17], WBRT with or with-
out radiosensitizers [18-23], chemotherapy with WBRT
[24-28], and WBRT with or without radiosurgery [29-33].
Methods
Clinical practice guideline development
This practice guideline was developed by Cancer Care
Ontario's Practice Guidelines Initiative (PGI), using the
methods of the Practice Guidelines Development Cycle
[34]. The practice guideline report is a convenient and up-
to-date source of the best available evidence on the role of
radiation therapy in adult patients with brain metastases,
developed through systematic reviews, evidence synthesis,
and input from practitioners in Ontario. The report is
intended to promote evidence-based practice. The PGI is
editorially independent of Cancer Care Ontario and the
Ontario Ministry of Health and Long-term Care. The PGI
has a formal standardized process to ensure the currency
of each guideline report. This process consists of the peri-
odic review and evaluation of the scientific literature and,
where appropriate, integration of this literature with the
original guideline information.
Evidence was selected and summarized by two members
of the Supportive Care Guidelines Group (SCGG) and
methodologists. Members of the SCGG disclosed poten-
tial conflict of interest information, reviewed the analysis
of the evidence, and prepared draft recommendations.
The membership of the SCGG includes palliative care
physicians, radiation and medical oncologists, radiation
therapists, psychiatrists, nurses, psychologists, an anes-
thetist, a surgeon, and methodologists. After reviewing the
evidence, the SCGG reached consensus on draft
recommendations.
External review by Ontario practitioners was obtained
through a mailed survey consisting of items that address
the quality of the draft practice guideline report and rec-
ommendations and whether the recommendations
should serve as a practice guideline. The efficacy of the
practitioner feedback survey process has been previously
described [35]. Final approval of the original guideline
report was obtained from the Practice Guidelines Coordi-
nating Committee (PGCC).
Interpretation of the evidence
Single brain metastasis
Two of the three trials using WBRT with or without surgi-
cal excision of a single brain metastasis detected an overall
survival benefit favouring the addition of surgery. The trial
that did not detect a benefit [4], however, included more
patients with poorer performance status and a higher pro-
portion of patients with extracranial disease as compared
to the other two trials.
The randomized trial by Patchell et al. [7] reported on the
use of surgery with or without WBRT. A significant reduc-
tion in brain recurrence rates was detected in the surgeryBMC Cancer 2005, 5:34 http://www.biomedcentral.com/1471-2407/5/34
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and WBRT arm, but there was no significant difference in
overall survival.
The methodologic quality of the studies was similar.
However, the description of withdrawals and dropouts
was variable. Only the Patchell trials [6,7] required mag-
netic resonance imaging (MRI)-confirmed single metasta-
sis. As such, those trials which relied on brain computed
tomography (CT) may have included patients with multi-
ple brain metastases rather than single. The benefit of add-
ing surgery in these patients with truly multiple brain
metastases may have been diminished.
In the trials examining the use of surgery and WBRT for
single brain metastasis, the WBRT doses were 3000 cGy/
10 fractions daily [4], 4000 cGy/20 fractions given twice a
day [5], 3600 cGy/12 fractions daily [6] and 5040 cGy/28
fractions daily [7].
The Radiation Therapy Oncology Group (RTOG) trial [31-
33] randomized 164 patients to WBRT and radiosurgery
boost versus 167 patients to WBRT alone. Overall, there
was no improvement in overall survival. An improvement
in one-year brain control rates was observed in the radio-
surgery boost arm. That trial included a predefined
hypothesis to detect a 75% median survival time improve-
ment (80% statistical power) in patients with single brain
metastasis. Median survival was 6.5 months in patients
with single brain metastasis treated with radiosurgery
boost as compared to 4.9 months in patients with single
brain metastasis treated with WBRT alone, p = 0.0393.
The evidence provided in the systematic review [3] sug-
gests that surgical resection of a single brain metastasis in
a patient with good performance status (Karnofsky Per-
formance Status [KPS] ≥  70) and stable or no extracranial
disease improves overall survival. The addition of WBRT
after surgical resection of a single brain metastasis
decreases brain recurrence rates. Based on one rand-
omized trial, the use of radiosurgery boost with WBRT was
reported to improve survival as compared to WBRT alone
in selected patients with single brain metastasis.
Multiple brain metastases
One randomized trial [8] examined the use of prednisone
with or without WBRT. This was an older trial, with a
small sample size of 48 patients, reported in the era prior
to CT scanning. The diagnosis of brain metastases was
based on outdated criteria; not contemporary CT or MRI
criteria. The proportion of patients with improved per-
formance status was similar in the steroid-alone and com-
bined WBRT and steroid arms (63% and 61%
respectively). The median survival of the steroid-alone
arm was 10 weeks as compared to 14 weeks in the com-
bined arm (p-value not stated). The methodologic quality
of that study was poor. Sample size calculations were not
described a priori, and a description of dropouts and with-
drawals was not provided. Statistical analyses were not
performed and therefore, the magnitude of benefit with
the use of WBRT over supportive care alone remains
unclear, particularly in patients with poor performance
status and/or active extracranial disease.
In several randomized controlled trials included in the
systematic review [3], a significant benefit in terms of
overall survival or symptom control was not detected with
altered dose-fractionation schedules as compared with a
standard dose-fractionation schedule of 3000 cGy in 10
fractions. The included studies were similar in methodo-
logic quality. Details of randomization (e.g., blinding of
randomization) were rarely provided, and complete fol-
low-up was variable among the studies. None of the trials
reported on the blinding of outcomes. Furthermore, none
of the negative trials commented on confidence intervals
or power calculations. A lack of sufficient high-quality evi-
dence precludes recommendations on which treatment
regimen(s) provide the greatest improvement in symptom
control.
In an attempt to improve the response of brain metastases
to treatment, radiosensitizers have been added to WBRT.
However, none of the five randomized trials [18-21,23]
detected a significant benefit in overall survival or brain
metastases response (CR + PR). None of the trials examin-
ing the use of radiosensitizers were double-blind. How-
ever, the events review committee (ERC) in the
gadolinium trial [22,23] was blinded to treatment assign-
ment and reviewed baseline and follow-up data. Based on
subgroup analysis, there was a suggestion that recursive
partitioning analysis (RPA) Class II lung cancer patients
with brain metastases may benefit from the use of motex-
afin gadolinium and WBRT. This is being further studied
in a phase III trial where patients with metastatic non-
small cell lung cancer are randomized to WBRT with or
without motexafin gadolinium.
In a non-blinded study, Ushio [24] randomized patients
with metastatic lung cancer to the brain to one of three
groups (WBRT alone, WBRT + chloroethylnitrosoureas, or
WBRT + chloroethylnitrosoureas + tegafur). No significant
difference in overall survival was seen among the three
groups. Brain response rates were significantly different
between the WBRT-alone arm and the WBRT + chlo-
roethylnitrosoureas + tegafur arm. However, 12 patients
were excluded from the evaluation due to protocol viola-
tions, which may have skewed the results of the study
given the small number of patients. Two patients died of
probable side effects of chemotherapy.BMC Cancer 2005, 5:34 http://www.biomedcentral.com/1471-2407/5/34
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For metastatic small-cell lung cancer, Postmus [25] found
no difference in overall survival in patients treated with
teniposide alone versus teniposide and WBRT. Although
the combined arm had higher brain response rates, there
is no comparison with WBRT alone. That study showed
that chemotherapy alone is inferior to the use of WBRT
and chemotherapy for improved brain metastases
response rates. However, it does not address the question
as to whether WBRT alone is superior or equivalent to
WBRT and chemotherapy for brain response and neu-
ropsychological outcomes.
For metastatic non-small cell lung cancer, Robinet [26]
found no difference in overall survival with early versus
delayed WBRT when given with chemotherapy. Delayed
WBRT was given to intracranial non-responders to chem-
otherapy. That non-blinded study was powered to detect
a 25% improvement in the six-month survival rate.
Approximately 13% of patients were inevaluable for
intracranial or extracranial response. However, withdraw-
als and drop-outs were described in terms of numbers and
reasons per group. There was a 21% overall response (CR
+ PR) after two cycles of chemotherapy alone and 20%
overall response to chemotherapy and early WBRT. Six-
month survival was no different between the two arms.
The results confirmed that chemotherapy alone may
reduce the size of brain metastases from metastatic non-
small cell lung cancer. The timing of WBRT in relation to
chemotherapy did not affect survival. However, it was not
possible to establish the optimal timing of WBRT when
given concurrently with chemotherapy from the results of
the Robinet trial [26].
Mornex [27] found no difference in cerebral response
rates between combined fotemustine and WBRT versus
fotemustine alone in patients with metastatic melanoma
to brain. However, there was a significant difference in
favour of the combined arm for time to cerebral progres-
sion. The most severe side effect was myelosuppression.
Delayed grade 3–4 neutropenia occurred in 46% of
patients in the fotemustine alone arm and 35% in the
combined arm. Delayed grade 3–4 thrombocytopenia
occurred in 44% of patients in the fotemustine-alone arm
and 38% in the combined arm. That trial did not address
the question of whether WBRT alone is superior or equiv-
alent to WBRT and fotemustine in terms of therapeutic
benefit and toxicity in patients with metastatic melanoma
to the brain.
Antonadou [28] found no difference in overall survival
for patients treated with WBRT and temozolamide chem-
otherapy versus WBRT alone. However, an improved
brain response rate was seen in the combined arm. Those
results were published in abstract form. Further trials are
needed to confirm a benefit in brain control with the
addition of chemotherapy to WBRT.
Three trials [29,30,33] reported on the use of radiosurgery
in addition to WBRT. Only one of those trials found a
benefit to the use of WBRT in addition to radiosurgery for
selected patients with 2–4 brain metastases; however, the
trial was small (n = 27 patients), and the results were
reported early at 60% accrual. The rate of local brain fail-
ure was 100% after WBRT and 8% in those treated with
boost radiosurgery. Furthermore, the 100% recurrence
rate in the WBRT arm was unusually high. There was no
significant difference in overall survival, 7.5 months for
WBRT and 11 months for patients in the WBRT and boost
radiosurgery arm, p = 0.22. As previously mentioned, the
RTOG trial [31-33] randomized 164 patients to WBRT
and radiosurgery boost versus 167 patients to WBRT
alone. No improvement in overall survival was detected.
In patients with single brain metastasis treated with radi-
osurgery boost median survival was 6.5 months as com-
pared to 4.9 months in patients with single brain
metastasis treated with WBRT alone, p = 0.0393. Another
trial published in abstract form [30] examined the use of
Gamma knife radiosurgery (GK RS), WBRT, or both in the
treatment of 1–3 brain metastases. There was no differ-
ence in overall survival. Local control rates were superior
for the GK RS and GK RS + WBRT arms. Subgroup analysis
for patients with single brain metastasis in this latter study
[30] was not reported. Thus, the use of radiosurgery
appears to improve 1-year local control of brain metas-
tases when used in conjunction with WBRT in selected
patients. There is Level 1 evidence (three trials) that over-
all survival is not improved with the addition of radiosur-
gery boost to WBRT as compared to WBRT. The optimal
timing of radiosurgery has not been elucidated. The ques-
tion of whether radiosurgery should be used as a boost
treatment with WBRT, at the time of relapse after WBRT,
or used alone, reserving WBRT for future extensive brain
relapse, remains unanswered.
Supportive Care Guidelines Group consensus
Originally proposed as a guideline topic for Cancer Care
Ontario's Neuro-Oncology Disease Site Group (NDSG),
in 2002 it was decided that the guideline would be devel-
oped under the auspices of the SCGG since the view was
to maintain a palliative focus. A separate practice guide-
line on the management of single brain metastases was
developed by the NDSG and is consistent with the current
guideline. Both the SCGG and NDSG reviewed all draft
versions of the guideline. Modifications were made at var-
ious stages as per the groups' feedback and the final ver-
sion was approved in February 2004.BMC Cancer 2005, 5:34 http://www.biomedcentral.com/1471-2407/5/34
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Results
Draft recommendations
Based on the evidence described above, the SCGG, with
the opinions of the NDSG, formulated the following draft
recommendations, which were subsequently sent out for
external review:
Target population
These recommendations apply to adult patients with a
clinical and radiographic diagnosis of brain metastases
(single or multiple) arising from cancer of any histology.
Radiotherapy and surgery for single brain metastasis
• Surgical excision is recommended, in addition to WBRT,
for patients with good performance status, minimal or no
evidence of extracranial disease, and a surgically accessible
single brain metastasis (single or multiple) arising from
cancer of any histology.
• Postoperative WBRT should be used to improve brain
control for patients who have undergone resection of a
single brain metastasis.
Radiotherapy for multiple brain metastases
• Whole brain radiotherapy is the recommended volume
of treatment for multiple brain metastases. Commonly
used dose-fractionation schedules are 3000 cGy in 10 frac-
tions or 2000 cGy in 5 fractions.
• There are no advantages of other altered dose-fractiona-
tion WBRT schedules in terms of overall survival or neu-
rologic function.
• The use of radiosensitizers is not recommended outside
research studies.
• The optimal use of radiosurgery in the treatment of
brain metastases remains to be defined. In patients with
one to three brain metastases (less than 3 cm in size) and
limited or controlled extracranial disease, radiosurgery
may be considered to improve local control either as
boost therapy with WBRT or at the time of relapse after
WBRT failure.
Chemotherapy and whole brain radiotherapy
• The use of chemotherapy as primary therapy for brain
metastases (with WBRT used for intracranial non-
responders) or the use of chemotherapy with WBRT to
treat brain metastases remains experimental.
Supportive care and whole brain radiotherapy
• Supportive care alone without WBRT is an option for
patients with poor performance status or widely dissemi-
nated progressive cancer.
Qualifying statements
• The number of patients included in the two trials com-
paring 3000 cGy in 10 fractions versus 2000 cGy in 5 frac-
tions for multiple brain metastases was small.
• In the trials examining the use of surgery and WBRT for
single brain metastasis, the WBRT doses were 3000 cGy/
10 fractions daily, 4000 cGy/20 fractions given twice
daily, 3600 cGy/12 fractions daily, and 5040 cGy/28 frac-
tions daily. As such, the use of 2000 cGy/5 fractions of
WBRT has not been studied directly in this scenario.
External review process – Ontario practitioner feedback
Feedback on the draft practice guideline report was
obtained through a mailed survey of 246 practitioners in
Ontario (26 neurosurgeons, 137 medical oncologists, and
83 radiation oncologists). The survey consisted of items
evaluating the methods, results, and interpretation of the
evidence and whether the draft recommendations should
be approved as a practice guideline. Written comments
were invited. The SCGG reviewed the results of the survey.
Results of practitioner feedback
One hundred nine responses were received out of the 246
surveys sent (44% response rate). A summary of the
results is provided in Table 1. Of the practitioners who
responded, 85 indicated that the report was relevant to
their clinical practice and completed the survey. The sur-
vey results indicated that 96% of respondents agreed with
the interpretation of the evidence and 94% agreed with
the draft recommendations as stated. Ninety-two percent
of respondents agreed that the report should be approved
as a practice guideline. Twenty-three respondents (27%)
also provided written comments. The final guideline rec-
ommendations, which appear at the end of this report,
were modified in accordance with the suggestions from
the external reviewers and were subsequently approved by
Cancer Care Ontario's Practice Guidelines Coordinating
Committee.
Practice Guidelines Coordinating Committee approval 
process
The practice guideline report was circulated to the PGCC
for review and approval. Four of eight members of the
PGCC completed and returned ballots. Three of these
members approved the practice guideline report as writ-
ten, while one member approved the guideline and pro-
vided a suggestion for consideration by the SCGG. The
suggestion was to revise the wording of the recommenda-
tion for single brain metastasis to "considered" rather
than "recommended" as the evidence for benefit is not
compelling. The SCGG agreed with the suggestion and
modified the guideline accordingly.BMC Cancer 2005, 5:34 http://www.biomedcentral.com/1471-2407/5/34
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Conclusions
Guideline recommendations
For adult patients with a clinical and radiographic diagno-
sis of brain metastases (single or multiple) arising from
cancer of any histology (except for choriocarcinoma and
other germ cell tumours, and hematologic malignancies),
we recommend that:
Radiotherapy and surgery for single brain metastasis
• Surgical excision should be considered for patients with
good performance status, minimal or no evidence of
extracranial disease, and a surgically accessible single
brain metastasis amenable to complete excision.
• Postoperative WBRT should be considered to reduce the
risk of tumour recurrence for patients who have under-
gone resection of a single brain metastasis.
• Radiosurgery boost with WBRT may also improve sur-
vival in select patients with unresectable single brain
metastases.
Radiotherapy for multiple brain metastases
• The whole brain should be irradiated for multiple brain
metastases. Commonly used standard dose-fractionation
schedules are 3000 cGy in 10 fractions or 2000 cGy in 5
fractions.
• Altered dose-fractionation WBRT schedules have not
demonstrated any advantages in terms of overall survival
or neurologic function relative to more commonly used
fractionation schedules.
• The use of radiosensitizers is not recommended outside
research studies.
• In select patients with up to four brain metastases (up to
4 cm in size) and limited or controlled extracranial dis-
ease, radiosurgery may be considered as a boost therapy
with WBRT to improve local tumour control. Radiosur-
gery boost may also improve survival in select patients
with unresectable single brain metastases.
Chemotherapy and whole brain radiotherapy
• The use of chemotherapy as the primary therapy for
brain metastases (with WBRT used for those whose intrac-
ranial metastases fail to respond) or the use of chemother-
apy with WBRT to treat brain metastases remains
experimental.
Supportive care and whole brain radiotherapy
• Supportive care alone without WBRT is an option (for
example, in patients with poor performance status and
progressive extracranial disease). However, there is a lack
of Level 1 evidence to guide practitioners as to which sub-
Table 1: Practitioner responses to eight items on the practitioner feedback survey.
Item Number (%)
Strongly agree or agree Neither agree nor disagree Strongly disagree or disagree
The rationale for developing a 
clinical practice guideline, as stated 
in the "Choice of Topic" section of 
the report, is clear.
82 (98) 1 (1) 1 (1)
There is a need for a clinical 
practice guideline on this topic.
70 (83) 12 (14) 2 (2)
The literature search is relevant 
and complete.
77 (94) 5 (6) 0
The results of the trials described 
in the report are interpreted 
according to my understanding of 
the data.
81 (96) 3 (4) 0
The draft recommendations in this 
report are clear.
81 (96) 1 (1) 2 (2)
I agree with the draft 
recommendations as stated.
79 (94) 2 (2) 3 (4)
This report should be approved as 
a practice guideline.
77 (92) 6 (7) 1 (1)
If this report were to become a 
practice guideline, how likely 
would you be to make use of it in 
your own practice?
Very likely or likely Unsure Not at all likely or unlikely
57 (68) 6 (7) 21 (25)BMC Cancer 2005, 5:34 http://www.biomedcentral.com/1471-2407/5/34
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sets of patients with brain metastases should be managed
with supportive care alone without WBRT.
To support the application of these recommendations in
clinical practice, the following qualifying statements
should be considered:
The number of patients included in the two trials compar-
ing 3000 cGy in 10 fractions versus 2000 cGy in 5 frac-
tions for multiple brain metastases was small. In the trials
examining the use of surgery and WBRT for single brain
metastasis, the WBRT doses were 3000 cGy in 10 fractions
daily, 4000 cGy in 20 fractions given twice daily, 3600
cGy in 12 fractions daily, and 5040 cGy in 28 fractions
daily. As such, the use of 2000 cGy in 5 fractions of WBRT
has not been studied directly in this scenario. The results
of the studies may not be generalizable to all tumour
types. The majority of the patients in the studies (except
the chemotherapy studies) had lung, breast, or colorectal
cancer primaries.
List of abbreviations used
cGy, centigray(s); cm, centimeter(s); CR, complete
response; CT, computed tomography; ERC, events review
committee; GK RS, gamma knife radiosurgery; Gy,
gray(s); KPS, Karnofsky performance status; met, metasta-
sis(es); MRI, magnetic resonance imaging; NDSG, Neuro-
Oncology disease site group; PGCC, Practice Guidelines
Coordinating Committee; PGI, Practice Guidelines Initia-
tive; PR, partial response; RPA, recursive partitioning anal-
ysis; RTOG, Radiation Therapy Oncology Group; SCGG,
Supportive Care Guidelines Group; WBRT, whole brain
radiotherapy.
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